SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Diabetes

PUBLISHER: Fairfield Market Research | PRODUCT CODE: 2141869

Cover Image

PUBLISHER: Fairfield Market Research | PRODUCT CODE: 2141869

GLP-1 and CGM Convergence Market Insights, Competitive Landscape, and Market Forecast - 2033

PUBLISHED:
PAGES: 269 Pages
DELIVERY TIME: 2-5 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF & Excel (Single User License)
USD 4995
Unprintable PDF & Excel (Multi User License upto 5 users)
USD 7295
Printable PDF & Excel (Enterprise License above 5 users)
USD 8495

Add to Cart

Description

Table of Contents

GLP-1 and CGM Convergence Market Projected to Reach US$3,659.17 Mn by 2033

Introduction

The global glp-1 and cgm convergence market is valued at US$650 Mn in 2026 and projected to reach US$3,659.17 Mn by 2033, at a CAGR of 28% during 2026-2033. Fairfield Market Research assesses the market through its published product, customer and geographical classifications. The forecast provides a common basis for evaluating commercial priorities across the study period.

Market Insights

The product type breakdown covers Integrated GLP-1/CGM Digital Platforms, Standalone CGM Devices with GLP-1 Data Integration and Others. The end user breakdown covers Individuals with Type 2 Diabetes, Weight Management Patients (Non-Diabetic) and Others. The distribution channel breakdown covers Direct-to-Consumer/Telehealth and Clinical/Provider-Prescribed. These distinctions help businesses assess which offerings and customer requirements fall within the market's scope. The global forecast should be read alongside these segment definitions rather than applied uniformly to every individual category.

Within the product type classification, Integrated GLP-1/CGM Digital Platforms and Standalone CGM Devices with GLP-1 Data Integration represent separate categories in the report. Keeping these categories distinct helps readers evaluate the fit of an offering before applying the overall market forecast to a specific commercial plan.

Within the end user classification, Individuals with Type 2 Diabetes and Weight Management Patients (Non-Diabetic) represent separate categories in the report. Keeping these categories distinct helps readers evaluate the fit of an offering before applying the overall market forecast to a specific commercial plan.

Within the distribution channel classification, Direct-to-Consumer/Telehealth and Clinical/Provider-Prescribed represent separate categories in the report. Keeping these categories distinct helps readers evaluate the fit of an offering before applying the overall market forecast to a specific commercial plan.

Drivers

Fairfield's growth discussion addresses integrated glp-1/cgm digital platforms, individuals with type 2 diabetes and direct-to-consumer/telehealth. These themes provide a starting point for assessing demand conditions and the requirements facing suppliers. Their commercial importance depends on the segment, customer and region concerned. Businesses can use the report's detailed discussion to connect these demand factors with their own portfolios and sales priorities.

Business Opportunity

The opportunity discussion highlights product type, end user and distribution channel. Companies evaluating expansion can compare these areas with their existing capabilities, route to market and customer needs. Segment selection and regional positioning remain central to assessing the relevance of the published forecast to an individual business.

Businesses considering Integrated GLP-1/CGM Digital Platforms can compare its customer requirements with those associated with Standalone CGM Devices with GLP-1 Data Integration. This comparison can help define a more focused portfolio, identify the appropriate sales audience and establish which questions require additional segment evidence before resources are committed.

Businesses considering Individuals with Type 2 Diabetes can compare its customer requirements with those associated with Weight Management Patients (Non-Diabetic). This comparison can help define a more focused portfolio, identify the appropriate sales audience and establish which questions require additional segment evidence before resources are committed.

Region Analysis

North America is identified in Fairfield's regional analysis as a leading market. The geographical scope covers North America, Europe, Asia Pacific, Latin America and Middle East & Africa. Regional comparisons should use the report's own market definitions and forecast period.

Key Players

  • Dexcom, Inc.
  • Abbott Laboratories
  • Novo Nordisk A/S
  • Eli Lilly and Company
  • Medtronic plc
  • Senseonics Holdings, Inc.
  • Roche Holding AG
  • Tandem Diabetes Care, Inc.
  • Insulet Corporation
  • Signos, Inc.

Segmentation

By Product Type

  • Integrated GLP-1/CGM Digital Platforms
  • Standalone CGM Devices with GLP-1 Data Integration
  • Others

By End User

  • Individuals with Type 2 Diabetes
  • Weight Management Patients (Non-Diabetic)
  • Others

By Distribution Channel

  • Direct-to-Consumer/Telehealth
  • Clinical/Provider-Prescribed

By Geography

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
Show more

Table of Contents

1. Executive Summary

  • 1.1. Global GLP-1 and CGM Convergence Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2026
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Porter's Five Forces Analysis
  • 2.6. Impact of Russia-Ukraine Conflict
  • 2.7. PESTLE Analysis
  • 2.8. Regulatory Analysis
  • 2.9. Price Trend Analysis
    • 2.9.1. Current Prices and Future Projections, 2025-2033
    • 2.9.2. Price Impact Factors

3. Global GLP-1 and CGM Convergence Market Outlook, 2020 - 2033

  • 3.1. Global GLP-1 and CGM Convergence Market Outlook, by Product Type, Value (US$ Mn), 2020-2033
    • 3.1.1. Integrated GLP-1/CGM Digital Platforms
    • 3.1.2. Standalone CGM Devices with GLP-1 Data Integration
    • 3.1.3. Others
  • 3.2. Global GLP-1 and CGM Convergence Market Outlook, by End User, Value (US$ Mn), 2020-2033
    • 3.2.1. Individuals with Type 2 Diabetes
    • 3.2.2. Weight Management Patients (Non-Diabetic)
    • 3.2.3. Others
  • 3.3. Global GLP-1 and CGM Convergence Market Outlook, by Distribution Channel, Value (US$ Mn), 2020-2033
    • 3.3.1. Direct-to-Consumer/Telehealth
    • 3.3.2. Clinical/Provider-Prescribed
  • 3.4. Global GLP-1 and CGM Convergence Market Outlook, by Region, Value (US$ Mn), 2020-2033
    • 3.4.1. North America
    • 3.4.2. Europe
    • 3.4.3. Asia Pacific
    • 3.4.4. Latin America
    • 3.4.5. Middle East & Africa

4. North America GLP-1 and CGM Convergence Market Outlook, 2020 - 2033

  • 4.1. North America GLP-1 and CGM Convergence Market Outlook, by Product Type, Value (US$ Mn), 2020-2033
    • 4.1.1. Integrated GLP-1/CGM Digital Platforms
    • 4.1.2. Standalone CGM Devices with GLP-1 Data Integration
    • 4.1.3. Others
  • 4.2. North America GLP-1 and CGM Convergence Market Outlook, by End User, Value (US$ Mn), 2020-2033
    • 4.2.1. Individuals with Type 2 Diabetes
    • 4.2.2. Weight Management Patients (Non-Diabetic)
    • 4.2.3. Others
  • 4.3. North America GLP-1 and CGM Convergence Market Outlook, by Distribution Channel, Value (US$ Mn), 2020-2033
    • 4.3.1. Direct-to-Consumer/Telehealth
    • 4.3.2. Clinical/Provider-Prescribed
  • 4.4. North America GLP-1 and CGM Convergence Market Outlook, by Country, Value (US$ Mn), 2020-2033
    • 4.4.1. U.S. GLP-1 and CGM Convergence Market Outlook, by Product Type, 2020-2033
    • 4.4.2. U.S. GLP-1 and CGM Convergence Market Outlook, by End User, 2020-2033
    • 4.4.3. U.S. GLP-1 and CGM Convergence Market Outlook, by Distribution Channel, 2020-2033
    • 4.4.4. Canada GLP-1 and CGM Convergence Market Outlook, by Product Type, 2020-2033
    • 4.4.5. Canada GLP-1 and CGM Convergence Market Outlook, by End User, 2020-2033
    • 4.4.6. Canada GLP-1 and CGM Convergence Market Outlook, by Distribution Channel, 2020-2033
  • 4.5. BPS Analysis/Market Attractiveness Analysis

5. Europe GLP-1 and CGM Convergence Market Outlook, 2020 - 2033

  • 5.1. Europe GLP-1 and CGM Convergence Market Outlook, by Product Type, Value (US$ Mn), 2020-2033
    • 5.1.1. Integrated GLP-1/CGM Digital Platforms
    • 5.1.2. Standalone CGM Devices with GLP-1 Data Integration
    • 5.1.3. Others
  • 5.2. Europe GLP-1 and CGM Convergence Market Outlook, by End User, Value (US$ Mn), 2020-2033
    • 5.2.1. Individuals with Type 2 Diabetes
    • 5.2.2. Weight Management Patients (Non-Diabetic)
    • 5.2.3. Others
  • 5.3. Europe GLP-1 and CGM Convergence Market Outlook, by Distribution Channel, Value (US$ Mn), 2020-2033
    • 5.3.1. Direct-to-Consumer/Telehealth
    • 5.3.2. Clinical/Provider-Prescribed
  • 5.4. Europe GLP-1 and CGM Convergence Market Outlook, by Country, Value (US$ Mn), 2020-2033
    • 5.4.1. Germany GLP-1 and CGM Convergence Market Outlook, by Product Type, 2020-2033
    • 5.4.2. Germany GLP-1 and CGM Convergence Market Outlook, by End User, 2020-2033
    • 5.4.3. Germany GLP-1 and CGM Convergence Market Outlook, by Distribution Channel, 2020-2033
    • 5.4.4. Italy GLP-1 and CGM Convergence Market Outlook, by Product Type, 2020-2033
    • 5.4.5. Italy GLP-1 and CGM Convergence Market Outlook, by End User, 2020-2033
    • 5.4.6. Italy GLP-1 and CGM Convergence Market Outlook, by Distribution Channel, 2020-2033
    • 5.4.7. France GLP-1 and CGM Convergence Market Outlook, by Product Type, 2020-2033
    • 5.4.8. France GLP-1 and CGM Convergence Market Outlook, by End User, 2020-2033
    • 5.4.9. France GLP-1 and CGM Convergence Market Outlook, by Distribution Channel, 2020-2033
    • 5.4.10. U.K. GLP-1 and CGM Convergence Market Outlook, by Product Type, 2020-2033
    • 5.4.11. U.K. GLP-1 and CGM Convergence Market Outlook, by End User, 2020-2033
    • 5.4.12. U.K. GLP-1 and CGM Convergence Market Outlook, by Distribution Channel, 2020-2033
    • 5.4.13. Spain GLP-1 and CGM Convergence Market Outlook, by Product Type, 2020-2033
    • 5.4.14. Spain GLP-1 and CGM Convergence Market Outlook, by End User, 2020-2033
    • 5.4.15. Spain GLP-1 and CGM Convergence Market Outlook, by Distribution Channel, 2020-2033
    • 5.4.16. Russia GLP-1 and CGM Convergence Market Outlook, by Product Type, 2020-2033
    • 5.4.17. Russia GLP-1 and CGM Convergence Market Outlook, by End User, 2020-2033
    • 5.4.18. Russia GLP-1 and CGM Convergence Market Outlook, by Distribution Channel, 2020-2033
    • 5.4.19. Rest of Europe GLP-1 and CGM Convergence Market Outlook, by Product Type, 2020-2033
    • 5.4.20. Rest of Europe GLP-1 and CGM Convergence Market Outlook, by End User, 2020-2033
    • 5.4.21. Rest of Europe GLP-1 and CGM Convergence Market Outlook, by Distribution Channel, 2020-2033
  • 5.5. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific GLP-1 and CGM Convergence Market Outlook, 2020 - 2033

  • 6.1. Asia Pacific GLP-1 and CGM Convergence Market Outlook, by Product Type, Value (US$ Mn), 2020-2033
    • 6.1.1. Integrated GLP-1/CGM Digital Platforms
    • 6.1.2. Standalone CGM Devices with GLP-1 Data Integration
    • 6.1.3. Others
  • 6.2. Asia Pacific GLP-1 and CGM Convergence Market Outlook, by End User, Value (US$ Mn), 2020-2033
    • 6.2.1. Individuals with Type 2 Diabetes
    • 6.2.2. Weight Management Patients (Non-Diabetic)
    • 6.2.3. Others
  • 6.3. Asia Pacific GLP-1 and CGM Convergence Market Outlook, by Distribution Channel, Value (US$ Mn), 2020-2033
    • 6.3.1. Direct-to-Consumer/Telehealth
    • 6.3.2. Clinical/Provider-Prescribed
  • 6.4. Asia Pacific GLP-1 and CGM Convergence Market Outlook, by Country, Value (US$ Mn), 2020-2033
    • 6.4.1. China GLP-1 and CGM Convergence Market Outlook, by Product Type, 2020-2033
    • 6.4.2. China GLP-1 and CGM Convergence Market Outlook, by End User, 2020-2033
    • 6.4.3. China GLP-1 and CGM Convergence Market Outlook, by Distribution Channel, 2020-2033
    • 6.4.4. Japan GLP-1 and CGM Convergence Market Outlook, by Product Type, 2020-2033
    • 6.4.5. Japan GLP-1 and CGM Convergence Market Outlook, by End User, 2020-2033
    • 6.4.6. Japan GLP-1 and CGM Convergence Market Outlook, by Distribution Channel, 2020-2033
    • 6.4.7. South Korea GLP-1 and CGM Convergence Market Outlook, by Product Type, 2020-2033
    • 6.4.8. South Korea GLP-1 and CGM Convergence Market Outlook, by End User, 2020-2033
    • 6.4.9. South Korea GLP-1 and CGM Convergence Market Outlook, by Distribution Channel, 2020-2033
    • 6.4.10. India GLP-1 and CGM Convergence Market Outlook, by Product Type, 2020-2033
    • 6.4.11. India GLP-1 and CGM Convergence Market Outlook, by End User, 2020-2033
    • 6.4.12. India GLP-1 and CGM Convergence Market Outlook, by Distribution Channel, 2020-2033
    • 6.4.13. Southeast Asia GLP-1 and CGM Convergence Market Outlook, by Product Type, 2020-2033
    • 6.4.14. Southeast Asia GLP-1 and CGM Convergence Market Outlook, by End User, 2020-2033
    • 6.4.15. Southeast Asia GLP-1 and CGM Convergence Market Outlook, by Distribution Channel, 2020-2033
    • 6.4.16. Rest of SAO GLP-1 and CGM Convergence Market Outlook, by Product Type, 2020-2033
    • 6.4.17. Rest of SAO GLP-1 and CGM Convergence Market Outlook, by End User, 2020-2033
    • 6.4.18. Rest of SAO GLP-1 and CGM Convergence Market Outlook, by Distribution Channel, 2020-2033
  • 6.5. BPS Analysis/Market Attractiveness Analysis

7. Latin America GLP-1 and CGM Convergence Market Outlook, 2020 - 2033

  • 7.1. Latin America GLP-1 and CGM Convergence Market Outlook, by Product Type, Value (US$ Mn), 2020-2033
    • 7.1.1. Integrated GLP-1/CGM Digital Platforms
    • 7.1.2. Standalone CGM Devices with GLP-1 Data Integration
    • 7.1.3. Others
  • 7.2. Latin America GLP-1 and CGM Convergence Market Outlook, by End User, Value (US$ Mn), 2020-2033
    • 7.2.1. Individuals with Type 2 Diabetes
    • 7.2.2. Weight Management Patients (Non-Diabetic)
    • 7.2.3. Others
  • 7.3. Latin America GLP-1 and CGM Convergence Market Outlook, by Distribution Channel, Value (US$ Mn), 2020-2033
    • 7.3.1. Direct-to-Consumer/Telehealth
    • 7.3.2. Clinical/Provider-Prescribed
  • 7.4. Latin America GLP-1 and CGM Convergence Market Outlook, by Country, Value (US$ Mn), 2020-2033
    • 7.4.1. Brazil GLP-1 and CGM Convergence Market Outlook, by Product Type, 2020-2033
    • 7.4.2. Brazil GLP-1 and CGM Convergence Market Outlook, by End User, 2020-2033
    • 7.4.3. Brazil GLP-1 and CGM Convergence Market Outlook, by Distribution Channel, 2020-2033
    • 7.4.4. Mexico GLP-1 and CGM Convergence Market Outlook, by Product Type, 2020-2033
    • 7.4.5. Mexico GLP-1 and CGM Convergence Market Outlook, by End User, 2020-2033
    • 7.4.6. Mexico GLP-1 and CGM Convergence Market Outlook, by Distribution Channel, 2020-2033
    • 7.4.7. Argentina GLP-1 and CGM Convergence Market Outlook, by Product Type, 2020-2033
    • 7.4.8. Argentina GLP-1 and CGM Convergence Market Outlook, by End User, 2020-2033
    • 7.4.9. Argentina GLP-1 and CGM Convergence Market Outlook, by Distribution Channel, 2020-2033
    • 7.4.10. Rest of LATAM GLP-1 and CGM Convergence Market Outlook, by Product Type, 2020-2033
    • 7.4.11. Rest of LATAM GLP-1 and CGM Convergence Market Outlook, by End User, 2020-2033
    • 7.4.12. Rest of LATAM GLP-1 and CGM Convergence Market Outlook, by Distribution Channel, 2020-2033
  • 7.5. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa GLP-1 and CGM Convergence Market Outlook, 2020 - 2033

  • 8.1. Middle East & Africa GLP-1 and CGM Convergence Market Outlook, by Product Type, Value (US$ Mn), 2020-2033
    • 8.1.1. Integrated GLP-1/CGM Digital Platforms
    • 8.1.2. Standalone CGM Devices with GLP-1 Data Integration
    • 8.1.3. Others
  • 8.2. Middle East & Africa GLP-1 and CGM Convergence Market Outlook, by End User, Value (US$ Mn), 2020-2033
    • 8.2.1. Individuals with Type 2 Diabetes
    • 8.2.2. Weight Management Patients (Non-Diabetic)
    • 8.2.3. Others
  • 8.3. Middle East & Africa GLP-1 and CGM Convergence Market Outlook, by Distribution Channel, Value (US$ Mn), 2020-2033
    • 8.3.1. Direct-to-Consumer/Telehealth
    • 8.3.2. Clinical/Provider-Prescribed
  • 8.4. Middle East & Africa GLP-1 and CGM Convergence Market Outlook, by Country, Value (US$ Mn), 2020-2033
    • 8.4.1. GCC GLP-1 and CGM Convergence Market Outlook, by Product Type, 2020-2033
    • 8.4.2. GCC GLP-1 and CGM Convergence Market Outlook, by End User, 2020-2033
    • 8.4.3. GCC GLP-1 and CGM Convergence Market Outlook, by Distribution Channel, 2020-2033
    • 8.4.4. South Africa GLP-1 and CGM Convergence Market Outlook, by Product Type, 2020-2033
    • 8.4.5. South Africa GLP-1 and CGM Convergence Market Outlook, by End User, 2020-2033
    • 8.4.6. South Africa GLP-1 and CGM Convergence Market Outlook, by Distribution Channel, 2020-2033
    • 8.4.7. Egypt GLP-1 and CGM Convergence Market Outlook, by Product Type, 2020-2033
    • 8.4.8. Egypt GLP-1 and CGM Convergence Market Outlook, by End User, 2020-2033
    • 8.4.9. Egypt GLP-1 and CGM Convergence Market Outlook, by Distribution Channel, 2020-2033
    • 8.4.10. Nigeria GLP-1 and CGM Convergence Market Outlook, by Product Type, 2020-2033
    • 8.4.11. Nigeria GLP-1 and CGM Convergence Market Outlook, by End User, 2020-2033
    • 8.4.12. Nigeria GLP-1 and CGM Convergence Market Outlook, by Distribution Channel, 2020-2033
    • 8.4.13. Rest of Middle East GLP-1 and CGM Convergence Market Outlook, by Product Type, 2020-2033
    • 8.4.14. Rest of Middle East GLP-1 and CGM Convergence Market Outlook, by End User, 2020-2033
    • 8.4.15. Rest of Middle East GLP-1 and CGM Convergence Market Outlook, by Distribution Channel, 2020-2033
  • 8.5. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Company Vs Segment Heatmap
  • 9.2. Company Market Share Analysis, 2025
  • 9.3. Competitive Dashboard
  • 9.4. Company Profiles
    • 9.4.1. Dexcom, Inc.
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Product Portfolio
      • 9.4.1.3. Financial Overview
      • 9.4.1.4. Business Strategies and Developments
    • 9.4.2. Abbott Laboratories
    • 9.4.3. Novo Nordisk A/S
    • 9.4.4. Eli Lilly and Company
    • 9.4.5. Medtronic plc
    • 9.4.6. Senseonics Holdings, Inc.
    • 9.4.7. Roche Holding AG
    • 9.4.8. Tandem Diabetes Care, Inc.
    • 9.4.9. Insulet Corporation
    • 9.4.10. Signos, Inc.

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!